Exercise-induced Pulmonary Arterial Hypertension
Overview
Affiliations
Background: The clinical relevance of exercise-induced pulmonary arterial hypertension (PAH) is uncertain, and its existence has never been well studied by direct measurements of central hemodynamics. Using invasive cardiopulmonary exercise testing, we hypothesized that exercise-induced PAH represents a symptomatic stage of PAH, physiologically intermediate between resting pulmonary arterial hypertension and normal.
Methods And Results: A total of 406 consecutive clinically indicated cardiopulmonary exercise tests with radial and pulmonary arterial catheters and radionuclide ventriculographic scanning were analyzed. The invasive hemodynamic phenotype of exercise-induced PAH (n=78) was compared with resting PAH (n=15) and normals (n=16). Log-log plots of mean pulmonary artery pressure versus oxygen uptake (V(.)o(2)) were obtained, and a "join-point" for a least residual sum of squares for 2 straight-line segments (slopes m1, m2) was determined; m2<m1="plateau," and m2>m1="takeoff" pattern. At maximum exercise, V(.)o(2) (55.8+/-20.3% versus 66.5+/-16.3% versus 91.7+/-13.7% predicted) was lowest in resting PAH, intermediate in exercise-induced PAH, and highest in normals, whereas mean pulmonary artery pressure (48.4+/-11.1 versus 36.6+/-5.7 versus 27.4+3.7 mm Hg) and pulmonary vascular resistance (294+/-158 versus 161+/-60 versus 62+/-20 dyne x s x cm(-5), respectively; P<0.05) followed an opposite pattern. An exercise-induced PAH plateau (n=32) was associated with lower o(2)max (60.6+/-15.1% versus 72.0+/-16.1% predicted) and maximum cardiac output (78.2+/-17.1% versus 87.8+/-18.3% predicted) and a higher resting pulmonary vascular resistance (247+/-101 versus 199+/-56 dyne x s x cm(-5); P<0.05) than takeoff (n=40). The plateau pattern was most common in resting PAH, and the takeoff pattern was present in nearly all normals.
Conclusions: Exercise-induced PAH is an early, mild, and clinically relevant phase of the PAH spectrum.
Physical exercise for pulmonary arterial hypertension diagnosis and therapy.
Lwin M, Masding A, McCabe C Int J Cardiol Congenit Heart Dis. 2025; 19:100565.
PMID: 40066343 PMC: 11891737. DOI: 10.1016/j.ijcchd.2025.100565.
Tarras E, Singh I, Kreiger J, Joseph P J Clin Med. 2025; 14(3).
PMID: 39941482 PMC: 11818252. DOI: 10.3390/jcm14030804.
Oliveros E, Mauri M, Pietrowicz R, Sadek A, Lakhter V, Bashir R J Clin Med. 2025; 13(24.
PMID: 39768625 PMC: 11677292. DOI: 10.3390/jcm13247702.
Coulis A, Levanon S, Randhawa G, Brailovsky Y, Raza F, Oliveros E Front Sports Act Living. 2024; 6:1477562.
PMID: 39635043 PMC: 11614647. DOI: 10.3389/fspor.2024.1477562.
Harder E, Rahaghi F, Leopold J, Systrom D, Washko G, Waxman A ERJ Open Res. 2024; 10(6).
PMID: 39624389 PMC: 11609945. DOI: 10.1183/23120541.00201-2024.